Abstract: Sertraline is a selective serotonin reuptake inhibitor widely metabolized in the liver by cytochrome P450 (CYP) enzymes. Besides, it is a P-glycoprotein substrate. Moreover, serotonin transporters and serotonin receptors are involved in its efficacy and safety. The aim of this study was to evaluate the role of polymorphisms of metabolizing enzymes, transporters and receptors on the pharmacokinetics, pharmacodynamics and tolerability of sertraline in healthy volunteers. Forty-six healthy volunteers (24 men and 22 women) receiving a 100-mg single oral dose of sertraline were genotyped for 17 genetic variants of CYP enzymes (CYP2B6, CYP2C9, CYP2C19, CYP2D6), ATP-binding cassette subfamily B member 1 (ABCB1), solute carrier family 6 member 4 (SLC6A4), 5-hydroxytryptamine receptor 2A (HTR2A) and 5-hydroxytryptamine receptor 2C (HTR2C) genes. Pharmacokinetic and pharmacodynamic parameters were similar in men and women. Polymorphisms in CYP2C19 and CYP2B6 genes influenced sertraline pharmacokinetics, with a greater effect of CYP2C19. Individuals carrying defective alleles for CYP2C19 and CYP2B6 showed higher area under the curve (AUC) and half-life (T 1/2 ). Moreover, CYP2C19*17 was related to a decreased AUC and T 1/2 . No significant effect was found for polymorphisms in CYP2C9, CYP2D6 and ABCB1 on sertraline pharmacokinetics. Sertraline had a small heart rate-lowering effect, directly related to maximum concentration (C max ) and the presence of ABCB1 minor alleles. Sertraline had no significant effect on blood pressure and QTc. There was a tendency to present more adverse drug reactions in women and individuals with higher AUC of sertraline, such as CYP2C19 intermediate metabolizers and CYP2B6 G516T T/T individuals.
Sertraline is an antidepressant belonging to the family of selective serotonin reuptake inhibitors (SSRIs), which acts blocking the serotonin transporters (SERT) in the presynaptic terminals [1] . It has shown similar efficacy but a better safety profile compared to classic tricyclic antidepressants [2, 3] . Sertraline hydrochloride is given in oral doses of 50-100 mg daily for the treatment of major depressive disorder (MDD), obsessive-compulsive disorder, social anxiety disorder (social phobia), panic disorder and post-traumatic stress disorder [4] . Sertraline exhibits linear pharmacokinetics, and peak plasma concentrations occur around 4-8 hr after a single oral dose. It exhibits high plasma protein binding, approximately 98%. Half-life (T " ) is about 24 hr [5] .
Sertraline is widely metabolized to N-desmethylsertraline, which does not contribute to clinical effects. At least five cytochrome P450 (CYP) isoforms are involved in sertraline Ndemethylation: CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 [6] , of which CYP2C19 seems to be the major enzyme involved in vivo [7, 8] , although CYP2B6 was shown to play a major role in an in vitro study [9] . Different variants located in these genes could alter enzyme activity and thus confer different metabolizer phenotypes, which could lead to higher or lower drug levels.
Both sertraline and its metabolite have high in vitro affinity for P-glycoprotein (P-gp) [10] , a drug transporter encoded by ABCB1 gene. Three single nucleotide polymorphisms (SNPs) in this gene (C3435T, C1236T and G2677T/A) are commonly studied together. Moreover, other polymorphisms in ABCB1 have been previously associated with remission and side effects of depression treated with sertraline [11] . It is necessary to clarify the influence of ABCB1 polymorphisms on the pharmacokinetics of sertraline, thus enabling a better understanding of the mechanisms underlying these differences in remission and side effects between individuals with different ABCB1 genotypes.
Additionally, several genes are involved in its efficacy and safety, such as serotonin transporters and serotonin receptors. Sertraline binds to serotonin transporter 1 (encoded by SLC6A4) blocking serotonin uptake, therefore increasing serotonin synaptic concentrations [12] . This gene has numerous polymorphic variations including those in 5-HTTLPR (serotonin transporter-linked polymorphic region), which is a length variation polymorphism associated with depression and other mood disorders [13] . The variable number of tandem repeats Author for correspondence: Francisco Abad-Santos, Clinical Pharmacology Department, Hospital Universitario de la Princesa, Diego de Le on 62, 28006 Madrid, Spain (e-mail francisco.abad@salud.madrid. org).
(VNTR) region in intron 2 of the gene, which involves 9-12 repeats of a 16/17 base pair unit [14] , appears to regulate transcriptional efficiency. Polymorphisms in several serotonin receptor genes have been associated with response or remission to SSRI drugs [15] ; thus, genetic variants within HTR2A and HTR2C may predict treatment outcome.
Most common sertraline adverse events (AEs) include gastrointestinal disturbances, anxiety, sexual dysfunction, impaired cognition [16] and even the possibility of developing serotonin syndrome [17] .
About 40% of patients do not reach a good response to SSRI treatment and about 54% do not reach remission [18, 19] . To date, there is not enough evidence to define the factors consistently that can predict response to an individual drug used for treating depression [18] . Pharmacogenetic analyses are crucial for improving antidepressant treatment [20] and could be helpful to explain the interindividual variability in drug response and thus may help predict treatment outcome. Therefore, our purpose was to study the role of polymorphisms of metabolizing enzymes, transporters and receptors on the pharmacokinetics, pharmacodynamics and tolerability of sertraline in healthy volunteers, avoiding confounding factors, such as the high number of concomitant treatments given to depressed patients.
Methods
Study population. Our study population comprised healthy volunteers from two bioequivalence clinical trials performed at the Clinical Trials Unit of Hospital Universitario de la Princesa (Madrid, Spain). The protocol complied with current Spanish legislation on clinical research in human beings and was approved by the Research Ethics Committee, duly authorized by the Spanish Drugs Agency and under the guidelines of good clinical practice. All individuals gave their written informed consent for both clinical trial and pharmacogenetics studies.
The inclusion criteria were as follows: non-smoking male and female volunteers, age 18-55 years, body mass index (BMI) within the 18.5-30.0 range, free from any organic or psychiatric conditions, with normal vital signs, electrocardiogram (ECG), medical records and physical examination. It was not allowed to take other drugs during the study. Individuals were free to withdraw from the study at any time.
Study design and procedures. We analysed the data of two bioequivalence clinical trials of two formulations of 100 mg sertraline tablets, after a single oral dose administration to healthy volunteers under fasting conditions. The clinical trials were randomized, openlabel, cross-over, two-period, two-sequence, single-centre studies, separated by a 7-day washout period, with blind determination of the plasma concentrations of sertraline.
Sertraline was administered with 200 mL of water. Individuals fasted from 10 hr before and 5 hr after drug administration. For the analysis of pharmacokinetics, 16 blood samples were obtained from baseline (before administration) to 96 hr after dosing. Samples were centrifuged for 10 min. at 3500 rpm (1900 9 g). All the plasma samples were stored at À30°C until its shipment to the external analytical laboratory.
Sertraline was measured using a validated liquid chromatographic/ tandem mass spectrometric method, with a lower limit of quantification of 0.1 ng/mL, similar to other published methods [21] .
Pharmacodynamic analysis. Blood pressure (BP), heart rate (HR) and 12-lead ECG were measured in supine position at pre-dose and 4.5 hr after dosing. The QT and HR values were automatically calculated by the ECG device. To correct the QT interval (QTc), we used the Bazett correction formula [22] . According to the International Council for Harmonisation E14 clinical guidance [23] , we considered QTc interval prolongation an absolute QTc interval greater than 450 milliseconds or a change from baseline in QTc interval greater than 30 milliseconds.
Pharmacokinetic
analysis. Pharmacokinetic parameters were calculated by non-compartmental methods using WinNonlin Professional, version 2.0 (Pharsight Corporation, Palo Alto, CA, USA). The maximum plasma concentration (C max ) and time to reach the maximum plasma concentration (T max ) were obtained directly from raw data. The area under the curve (AUC) was calculated from the administration to the last measured concentration (AUC t ) by linear trapezoidal integration. The total AUC from administration to infinity (AUC ∞ ) was calculated as the sum of AUC t and the residual area (C t divided by k e , with C t as the last measured concentration and k e as the apparent terminal elimination rate, which was estimated by log-linear regression from the terminal portion of the log-transformed concentration-time plots). Half-life (T 1/2 ) was calculated by dividing 0.693 by k e . As extrapolated AUC was always lower than 20%, values of AUC correspond to AUC ∞ unless otherwise indicated.
The total drug clearance adjusted for bioavailability (Cl/F) was calculated by dividing the dose by the AUC ∞ and adjusting for weight. Volume of distribution adjusted for bioavailability (V d /F) was calculated as Cl/F divided by k e . AUC and C max were adjusted for dose and weight (AUC/dW and C max /dW, divided by the dose-by-weight ratio) and logarithmically transformed for statistical analysis. We analysed both formulations for each individual as both studies showed bioequivalence. Then, we took the mean between formulations for each parameter to reduce the intraindividual variability.
Safety assessment. The safety and tolerability of sertraline were assessed by clinical evaluation of AEs and other parameters including vital signs, physical examinations and ECGs. During the course of the study, volunteers were asked whether they had experienced any AE and, additionally, those AEs spontaneously notified by the volunteer were documented. Karch and Lasagna criteria [24] were used to determine causality. According to these criteria, AEs can be classified as definite, probable, possible, unlikely and unrelated. Only those AEs that were definite, probable or possible were considered as adverse drug reactions (ADRs) and taken into account for statistical analysis.
Genotyping. DNA was extracted from 1 mL of peripheral blood samples using an automatic DNA extractor (MagNa Pure â System; Roche Applied Science, Indianapolis, IN, USA) and quantified spectrophotometrically in a NanoDrop â ND-1000 Spectrophotometer (Wilmington, DE, USA). All analysed polymorphisms were selected given the pharmacokinetics and pharmacodynamic parameters of sertraline. Not all volunteers were genotyped for all variants as we excluded those samples with no clear amplification profile. 5-HTTLPR amplification was performed using primers previously described [25] , which resulted in a 375-or 419-bp fragment (corresponding to 14 or 16 repeats). Products were separated and detected in ethidium bromide 2.5% NuSieve3:1 agarose gel.
The serotonin transporter gene intron 2 region (SLC6A4 VNTR) was amplified using primers previously defined [26] , which resulted in a 250-, 267-and/or 300-bp fragment corresponding to 9, 10 or 12 repeats. Products were separated and detected in ethidium bromide 2.5% NuSieve3:1 agarose gel. Some samples were sequenced in a fragment sequencer ABI PRISM 3130 â (Applied Biosystems, Foster City, CA, USA) and used as positive controls.
HTR2A T102C and HTR2C -759C/T were determined by real-time PCR in a Light Cycler 4.0 system (Roche Bioscience, Mannheim, Germany). The CYP2D6*3, *4 and *5 and CYP2C19*2, *3 and *17 polymorphisms were studied by real-time PCR using LightCyler â 2.0 instrument (Roche Diagnostics, Mannheim, Germany). A set of primers and probes were designed by TIB MOLBIOL (Berl ın, Germany) for this purpose. ABCB1 polymorphisms (C3435T, C1236T, G2677T/A), CYP2B6 G516T polymorphisms and CYP2D6*6, *7 and *9 polymorphisms were genotyped using a StepOnePlus TM PCR instrument (Applied Biosystems).
To determine the copy number variations (CNVs) in the CYP2D6 gene, we used a TaqMan Copy Number Assay (Applied Biosystems) (Assay ID: Hs00010001_cn), which detects a specific sequence on exon 9. For statistical reasons, all the samples were run in quadruplicate in a StepOnePlus TM PCR instrument (Applied Biosystems). We used a positive control from Coriell Institute with a known copy number of CYP2D6 (three copies, Coriell ID: NA17221). The assay was performed with an endogenous control, TaqManRNase P Copy Number Reference Assay (Assay ID: 4403326; Applied Biosystems). To determine the exact number of CYP2D6 copies, we used CopyCaller Software (Applied Biosystems) that uses the comparative DDCT method [27] .
Statistical analysis. Statistical analysis was performed with the SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). We considered statistically significant p values lower than or equal to 0.05. The Hardy-Weinberg equilibrium was estimated for all analysed variants. Deviations from the equilibrium were detected by comparing the observed and expected frequencies using a Fisher's exact test based on the De Finetti program (available at http://ihg.gsf.de/cgi-bin/hw/ hwa1.pl). Differences in the genotypic frequencies according to sex were determined using a corrected Pearson chi-square test. Differences in pharmacokinetic parameters between individuals with diverse genotypes and sex were statistically analysed by a parametric univariate analysis (t-test or ANOVA). Chi-square test was used to compare the incidence of ADRs between different genotypes. The correlation of AUC and C max with changes in BP, QTc and HR was analysed by lineal regression. The main analysis consisted of a multiple regression analysis (logistic regression for ADRs) including factors with p ≤ 0.05 in the univariate analysis. For this purpose, categorical variables with more than two categories, such as polymorphisms, were analysed using dummy variables. p ≤ 0.05 was regarded as statistically significant.
In order to simplify the analysis, CYP2C9 and CYP2C19 genotypes were classified according to the number of functional alleles into PM (poor metabolizers) (two defective alleles), IM (intermediate metabolizers) (one defective allele), EM (extensive metabolizers) (two functional alleles) and UM (ultra-rapid metabolizers) (carriers of *17 variant of CYP2C19); two individuals with CYP2C19*2/*17 genotype were considered as UM as their pharmacokinetic parameters were more similar to those in that category. CYP2D6 genotypes were also classified in four phenotypes (PM, IM, EM and UM) according to the method used by Gaedigk et al., which is based on the functionality of alleles [28] .
Results
Demographic and genotypic characteristics. Forty-eight Caucasian healthy volunteers were included in two sertraline studies, of which 46 (24 men and 22 women) completed the study and participated in the pharmacogenetics study. Average age was similar between men and women (23.5 AE 2.6 years and 23.0 AE 2.5 years, respectively), but men weighed more (75. in women, no sex differences were found after adjusting for weight and dose. Women showed higher T 1/2 (p = 0.05), but this difference disappeared after adjusting for polymorphisms in the multivariate analysis. The univariate analysis revealed an association between some pharmacokinetic parameters and polymorphisms in CYP2B6 and CYP2C19 (table 3) . Individuals with CYP2C19 IM phenotype and carriers of one or two defective alleles of CYP2B6 showed higher AUC and T 1/2, although AUC was not significant for CYP2B6 (p = 0.069) ( fig. 1) . No differences were found in C max or Cl/F. CYP2C19 UM showed lower AUC and T 1/2 than EM, along with higher Cl/F, although it did not reach statistical significance for T 1/2 (p = 0.322) and Cl/F (p = 0.078) ( fig. 1) . The results did not change when CYP2C19 *2/*17 individuals were excluded from the analysis. After multiple regression analyses, most of these associations remained statistically significant (table 3) .
We found no significant association between polymorphisms in CYP2C9, CYP2D6 and ABCB1 with pharmacokinetics of sertraline. However, individuals carrying two mutated alleles in any of the three SNPs of ABCB1 showed lower AUC and T 1/2 (table 3), but these differences did not reach statistical significance. Surprisingly, CYP2C9 PM showed shorter T 1/2 than EM, although it was not significant (p = 0.068).
Pharmacodynamic analysis.
Sertraline did not produce a significant change in BP and QTc, despite one man who had a QTc prolongation (increase of 32 msec. from baseline). However, sertraline had a slight HR-lowering effect as it decreased 3.54 AE 1.61 bpm at 4.5 hr after dosing when compared to baseline (p = 0.031). Decrease in HR showed a direct relationship with C max , but not with AUC ( fig. 2) . Women showed lower BP and higher HR and QTc in comparison with men. However, the pharmacodynamic effect of sertraline was similar in men and women.
There was no significant association between the studied polymorphisms in SLC6A4, HTR2A and HTR2C and pharmacodynamics. However, we found statistically significant association between polymorphisms in ABCB1 and differences in HR, as shown in fig. 2 : individuals C3435T homozygous T/T or G2677T/A homozygous A/A showed higher decrease in HR (p = 0.002 and p = 0.017). ABCB1 C1236T homozygous T/T also showed higher decrease in HR although it was not statistically significant (p = 0.059).
Adverse drug reactions.
Both tests and reference formulations showed similar safety profile. No severe, serious or life-threatening AEs were registered. A total of 34 volunteers (73.9%) experienced at least one ADR. The most frequent were insomnia (43.5%), nausea/ vomiting (34.8%), headache (30.4%), dizziness (17.4%), dry mouth (17.4%), epigastralgia/heartburn (17.4%) and diarrhoea (15.2%).
The incidence of ADRs was higher in women than in men (86.4% and 62.5%, respectively), but it was not statistically significant (p = 0.066). The incidence of insomnia, nausea/ vomiting and dry mouth was significantly higher in women compared to men (59.1% versus 29.2%, p = 0.041; 54.5% versus 16.7%, p = 0.007; and 31.8% versus 4.2%; p = 0.013, respectively).
There was no significant association between the studied polymorphisms and the incidence of ADRs (table 4) . However, we observed a tendency to present more ADRs in individuals with higher AUC (CYP2C19 IM and CYP2B6 T/T). Moreover, individuals carrying homozygous mutations in any of the three SNPs of ABCB1 showed lower incidence of ADRs, maybe because they showed lower AUC (table 3) . Individuals carrying SLC6A4 short 5-HTTLPR variant and 10-repeats of the VNTR showed also lower incidence.
Individuals who experienced ADRs (both global incidence and all the types separately analysed) showed higher AUC (914.8 AE 345.5 ng/hr/mL versus 789.2 AE 326.0 ng/hr/mL; p = 0.239) when compared to those without any ADR. However, there were no apparent differences in C max (31.1 AE 6.1 ng/mL versus 32.0 AE 8.1 ng/mL; p = 0.853).
Discussion
Sertraline, as a SSRI, is a first-line antidepressant widely prescribed for the treatment of MDD [29] . However, only 60-80% of patients respond to this treatment and many have side effects that require a change in treatment [4] . Patients suffering from MDD are three times more likely to discontinue the prescribed treatment when compared to non-depressed patients [30] ; thus, given the high prevalence of this disease (approximately 4.7% of the world population) [31] and the lack of adherence, it would be critical to know about the pharmacogenetic basis influencing the response to sertraline, thus helping clinicians in the management of patients with MDD [20, 32] .
Although several pharmacogenetic studies about sertraline have been published, this is the first pharmacogenetic study evaluating together the influence of many polymorphisms in enzymes, transporters and receptors on the pharmacokinetics and pharmacodynamics of sertraline in a well-controlled population of individuals. Sertraline pharmacokinetics.
In a study carried out in 3858 women and 1594 men, Thiels et al. [33] aimed to evaluate the sex differences in the treatment of depressed outpatients with sertraline, finding no differences. Accordingly, in our study, we did not find an influence of sex on the pharmacokinetic parameters of sertraline, considering the differences we found disappeared after adjustment for weight and polymorphisms. The fact that multiple enzymes are involved in sertraline metabolism suggests that there could be more than one single enzyme or polymorphism that could have an impact on the pharmacokinetics of sertraline [9] . We have described an association between CYP2C19 and CYP2B6 polymorphisms and pharmacokinetics parameters of sertraline, which is consistent with previous studies [7] [8] [9] .
Concerning individuals with different CYP2C19 genotypes, PM have previously exhibited clear differences in the disposition of sertraline [8] . Moreover, practice guidelines recommend dose changes, therapeutic drug monitoring or alternative drugs for CYP2C19 PM treated with sertraline [7, 34] . Although we have no CYP2C19 PM individuals to compare, our results are consistent with those previously reported, as CYP2C19 IM showed higher AUC of sertraline compared to EM [35] . While the CYP2C19 *17 allele has previously failed to demonstrate a significant influence on the serum concentrations of sertraline [36, 37] , the CYP2C19 UM phenotype has been linked to lower serum concentrations of other antidepressants, such as escitalopram [38] . In our results, the critical effect of the *17 allele is clear, as it has an impact on sertraline pharmacokinetics, reducing 26% AUC in heterozygous individuals. In case of CYP2C19 UM patients who do not respond to adequate maintenance doses of sertraline, clinicians should consider an alternative SSRI not metabolized by CYP2C19 [34] , because lower levels of the parent drug in those UM individuals could imply increased risk of therapeutic failure.
Regarding CYP2B6, it has been reported that *6 and *9 variants had a significant decreasing effect on sertraline metabolism in MDD patients [37] . The G516T SNP present in both variants is recognized as the central sequence variation for severely reduced expression and function of CYP2B6 enzyme [37] . As homozygous T/T individuals have shown reduced metabolism and thus higher concentrations of sertraline, we concluded that patients carrying the T allele of CYP2B6*6 G516T SNP could possibly be at higher risk of ADRs.
Comparing the involvement of CYP2C19 and CYP2B6 on sertraline pharmacokinetics, we consider that CYP2C19 is more important as carrying one defective allele of CYP2C19 increased 38% AUC and 24% T 1/2 compared with wild-type, while carrying one defective allele of CYP2B6 increased 16% AUC and 9% T 1/2 . Carrying two defective alleles of CYP2B6 increased 60% AUC and 48% T 1/2, but we did not have individuals with two CYP2C19-defective alleles to compare.
We were not able to demonstrate association between polymorphisms in CYP2C9 and CYP2D6 and the pharmacokinetics of sertraline. This result could be due to the other P450 isoforms which are playing the major role. Indeed, it has been previously alleged that genotyping of CYP2C9 polymorphism has no decisive utility in psychiatry [7] . Moreover, it has been indicated that CYP2D6 does not play an important role in the metabolism of sertraline [39] .
P-gp expression can be found in specialized epithelial cells of secretory/excretory organs and in endothelial cells of capillary blood vessels at blood-tissue barriers such as the brain-blood barrier (BBB) or the placenta [40] . Due to its
CYP2B6 rs3745274
T/T G/T G/G AUC (ng·h/ml) 2,000,000 1,500,000 1,000,000 500,000 ,000 particular location, P-gp can have great impact in the processes of drug absorption, distribution, metabolism and excretion [41, 42] . Therefore, P-gp expression level and differences in functionality may influence the pharmacokinetics of certain drugs [43] . Multiple studies have attempted to identify associations between diverse SNPs in ABCB1 and pharmacokinetics of different drugs, turning out into diverse and inconsistent results [44, 45] . According to our knowledge, there is not any study that demonstrates an effect of ABCB1 polymorphisms on sertraline pharmacokinetics. We failed to find association between ABCB1 SNPs and the pharmacokinetics of sertraline, although individuals carrying two mutated alleles tended to have lower AUC and T 1/2 . In a previous study about trazodone, we also found lower AUC and T 1/2 and higher Cl/F in individuals T/T homozygous for C3435T [46] . This could explain why T allele homozygotes demonstrated significantly poorer responses to sertraline in our study [47] , although other studies found no association of the analysed polymorphisms with the time to remission in patients treated with sertraline or other antidepressants [11, 48] .
Sertraline pharmacodynamics and adverse events. The significant differences found in BP and HR according to sex are well-known aspects [49] ; women presented lower BP and higher HR compared to men. Besides that, the longer QTc shown by women may be due to genetic or hormonal differences [50] . Sertraline had no relevant effects on BP and ECG; however, it had a small effect decreasing HR, which was not clinically relevant. This effect was related to ABCB1 polymorphisms; therefore, P-gp could be involved in sertraline transport in the heart, as differences in P-gp expression could vary intracardiac concentrations and effects of therapeutic agents and cardiotoxic drugs [51] .
No sex differences in side effects have been previously described in patients treated with sertraline [33] . Nevertheless, in our study, we observed a higher incidence of several ADRs in women. These differences can be explained by the fact that women weight was lower than men: as they received the same dose, they reached higher concentrations. Therefore, considering the potential sex differences in the pharmacokinetics of antidepressants could help avoid ADRs and guarantee satisfactory treatment outcome [52] , Even though it was not significant, we observed a tendency in those individuals showing the phenotypes with reduced function of CYP2C19, CYP2B6 and CYP2D6 to present higher incidence of ADRs, which could be due to the fact they accumulated higher levels of the drug. Likewise, those individuals with ADRs showed higher AUC of sertraline, although it was not statistically significant.
The lower incidence of ADRs registered in ABCB1 T/T or A/A genotypes is consistent with the expected, as they showed lower levels of the drug. However, it has been previously described that C3435T common homozygous (C/C) individuals had fewer side effects when treated with escitalopram or sertraline compared to those T allele carriers [47] . These contradictory results need to be evaluated in other studies in order to elucidate whether these or other polymorphisms in ABCB1 can alter the metabolism, elimination and, as a consequence of those, the risk of suffering an ADR. Regarding SLC6A4, the S allele of 5-HTTLPR polymorphism is associated with a reduction in transcriptional efficiency compared to the L allele, which confers the wild-type genotype [53] . However, we failed to demonstrate any relationship between this variation and differences in safety. The long allele (12-repeat variant) of VNTR is associated with greater gene expression, better therapeutic outcome and safety profile [14] . In our study, although it was not significant, individuals carrying 12-12 genotype for SLC6A4 VNTR showed a trend to present higher rate of ADRs, which is consistent with a previous study where patients with 12-12 genotype treated with SSRIs suffered up to four times more side effects [54] .
The serotonin receptor 5-HT2A binding kinetics are altered in MDD [55] . Carriers of one or two C alleles of HTR2A T102C polymorphism (rs6313) show different outcome when treated with antidepressants and greater efficacy when compared to T/T homozygotes [56] . The -759C/T SNP (rs3813929) is located in the serotonin receptor HTR2C, and the presence of T allele showed borderline significant association with the incidence of life-time MDD [57] . However, in our study, we could not prove any relationship between these variations and differences in sertraline safety.
The limitation of our study is that it was performed after single-dose administration to healthy individuals, which prevents us from assessing long-term effectiveness and safety. Pharmacokinetics, pharmacodynamics and tolerability might vary in depressive patients receiving chronic treatment. It is important to take into account that these results must be interpreted with caution given the small sample size. However, a single-dose design in healthy individuals can assess the effect of genetic polymorphisms on sertraline without other confounding factors, such as smoking or concomitant treatments. Further studies are needed to increase the statistical power of these results. The validity of these results needs to be confirmed with similar settings and by studies in patients receiving chronic sertraline treatment. It is necessary to perform clinical trials in patients to confirm the utility of these polymorphisms in the treatment of depression. Indeed, a recent clinical trial showed that pharmacogenetic-guided treatment resulted in a significant improvement of MDD with a reduction in side effects [58] .
Conclusions
Pharmacokinetics of sertraline is not affected by sex. Polymorphisms in CYP2C19 and CYP2B6 influence sertraline pharmacokinetic parameters, as individuals with defective alleles show increased AUC and T 1/2 , with polymorphisms in CYP2C19 having a greater impact. Polymorphisms in CYP2C9, CYP2D6 and ABCB1 do not play a relevant role in the pharmacokinetics of sertraline.
Sertraline has no relevant effects on BP and ECG, but it produces a small decrease in HR that is related to the minor alleles of ABCB1 SNPs. There is a tendency to suffer more ADRs in women and individuals with higher AUC, especially for CYP2C19 IM and CYP2B6 T/T. For this reason, taking pharmacogenetic factors into account may help to improve antidepressant therapy, thus enabling a better treatment outcome and safety.
Future Perspective
Pharmacogenetics can help to personalize antidepressant treatment. In case of sertraline, this study confirms the effect of CYP2C19 and CYP2B6 enzymes on sertraline pharmacokinetics. According to our knowledge, this is the first study that goes further and evaluates simultaneously the effect of SNPs in other CYP450 enzymes apart from those already known, transporters and receptors on sertraline in healthy volunteers, avoiding confounding factors, such as the high number of concomitant treatments given to depressed patients. However, due to the small sample size, further studies are needed to confirm whether there is an association of specific polymorphisms in ABCB1, which could alter the disposition of sertraline and, thus, its pharmacological effect. 
Summary Points
Background. Sertraline, as a SSRI, is a first-line antidepressant widely prescribed for the treatment of depression. About 40% of patients do not reach a good response to SSRI. Therefore, pharmacogenetic analyses could be helpful to explain the interindividual variability in drug response.
Materials and methods.
• We evaluated the relationship of polymorphisms in CYP2B6, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR2A and HTR2C on the pharmacokinetics, pharmacodynamics and adverse effects of sertraline.
• 46 healthy volunteers, receiving a 100-mg single dose of sertraline, were genotyped for 17 genetic variants by real-time PCR.
• Differences in pharmacokinetic and pharmacodynamic parameters and incidence of ADRs were statistically analysed by univariate and multivariate analyses.
Results and conclusion.
• Sertraline pharmacokinetics is not affected by sex.
• Polymorphisms in CYP2C19 and CYP2B6 influence the pharmacokinetic parameters of sertraline, with greater effect of CYP2C19, but polymorphisms in CYP2C9, CYP2D6 and ABCB1 do not.
• Sertraline has no relevant effects on blood pressure and ECG, but produces a small decrease in heart rate related to the minor alleles of ABCB1.
• There is a tendency to suffer more ADRs in women and individuals with higher AUC, especially in CYP2C19 IM and individuals with CYP2B6 T/T genotype.
• Taking pharmacogenetic factors into account may help to improve antidepressant therapy, allowing better treatment outcome and patient safety.
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